The new round of funding for the $22.3 million Biomedical Translation Bridge (BTB) program is now open.
An initiative of the Medical Research Future Fund (MRFF) and operated by MTPConnect, the BTB program is offering up to $1 million to support development and commercialisation of new biological, pharmaceutical, medical and health technology projects.
This is the second round of the BTB program. Round one, announced in December 2019, saw eight projects selected to share in funding of $5.9 million following a competitive application process.
MTPConnect Managing Director and CEO, Dr Dan Grant, says the BTB program is a unique opportunity for Australian innovators to take their research to the next stage along the translation and commercialisation pathway.
“We’re looking to support SMEs and research organisations conducting research projects that provide innovative solutions in any disease area using any therapeutic modality or medical technology," Dr Grant adds.
“With applications only open for three weeks, from Monday, the Australian research community needs to move quickly to take advantage of the substantial funding on offer.”
MTPConnect is delivering the BTB program in partnership with BioCurate (Melbourne and Monash Universities), UniQuest (University of Queensland), the Medical Device Partnering Program (led by Flinders University) and the Bridge and BridgeTech programs (Queensland University of Technology).
The BTB program is uniquely positioned to provide applicants with expert mentoring from these partners, that provides scientific expertise and commercial acumen to support projects in their translation to proof of concept.
“The successful projects we invest in through the BTB program will lead to new therapies, technologies and medical devices to improve the health of Australians and deliver real impact to people all over the world,” Dr Grant explains.
Opening Monday 17 February, applications to the BTB program will be open until 5:00PM (AEDT) on Friday, 6 March 2020. Details can be found at the BTB page.